

ASML

Price EUR84.66

Bumpy road ahead

Fair Value EUR81 (-4%)

SELL

Bloomberg	ASML.NA
Reuters	ASML.AS
12-month High / Low (EUR)	103.8 / 71.8
Market Cap (EURm)	36,686
Ev (BG Estimates) (EURm)	35,260
Avg. 6m daily volume (000)	1,276
3y EPS CAGR	21.9%

Following yesterday's Q1 results (see our [first take](#)) and conference call, we continue to have doubts over mid-term visibility and system demand. Industry habits regarding the new node ramp are changing and we believe they add challenges for ASML to deliver its 2020 plan (targeting FY20e sales of EUR10bn). In addition, upcoming EUV sales recognition will have a negative impact on the group's margin. We have updated our model and are maintaining our Sell recommendation and FV of EUR81.

ANALYSIS

- Industry habits regarding new node ramp is changing.** The group highlighted a change in customer habits regarding new node ramp. Management noted that 28nm capacity is still increasing and generating orders of DUV systems, while only a few customers plan to adopt 10nm in the near term. As a result, we believe this should result in a rapid but short increase in orders compared to a longer wave of orders as seen in the past.
- Bookings should improve in Q2.** In our first take published yesterday (see [here](#)), we highlighted a particularly low level of bookings in Q1 (down 29% compared to Q4). During the conference call, management reassured on this point, stating that we should expect an improvement in bookings in Q2. We will keep a close eye on this data since it may be a leading indicator of H2 momentum.
- Compared to H1, H2 should be flat in Memory, up in Logic and Service & Field options.** In 2016, the memory segment should remain under pressure due to high capacity (high price pressure) and generate lower investments than in 2015. As expected, Logic should be driven by 10nm ramp over 2016 but the pace of the ramp is out of ASML's control and depends on customer's momentum and performance in the ramp of this new node. Finally, regarding Service & field options, it is expected to continue to growth at a 10% yoy rate in FY16. As a result, we expect to see System sales at about EUR4.23bn (flat compared to FY15 with H2-16 up 6.3% compared to H1-16) and Services & field option sales at about EUR2.26bn (+10% yoy)
- Reuse, a rising concern.** From yesterday's conference call, we understand that the group sees higher customer interest in reuse (upgrade of tool to be used for newer node), however management added it has been factored into the 2020 plan by the group (targeting EUR10bn of sales by 2020) and says it is on track with the company's expectations so far. We remind that we highlighted this risk in our previous comment (early April) and we believe the evolution of reuse deserves attention during future publications as it might influence DUV tools sales momentum over the LT, particularly after EUV introduction.
- One more EUV system to be shipped during Q2, then four/five in H2.** We believe that EUV revenue recognition should be quicker in 2016 but most of 2016 EUV shipments will be recognised in 2017. Note that EUV sales are recognised only after performance achievement at customer sites which might cause an important delay between EUV system shipment and sales recognition. Depending on contracts signed with customers, performance measures can be achieved earlier or later in the test process impacting negatively the visibility on total group sales.
- Margin pressure is due to EUV.** Finally, the group remind that guidance for 42% GM is due to partial payment of EUV system in Q2 (EUR110m in Q2 sales guidance). However, we think that the group was unclear regarding changes in the margin over the mid-term with EUV revenue recognition accelerating. As a result, we adopt a more cautious scenario with FY16 GM of 43.6% compared to 45.6% used previously. This margin pressure should lower in FY17 thanks to higher efficiency of the production leading to higher margin on EUV systems (we use a 22%/41%/45% gross margin on EUV systems for FY16/17/18e)

VALUATION

- We have updated our model to include Q1 results and new Q2 2016 guidance.** We also adopt a more cautious approach regarding gross margin for 2016 (lowered from 45.6% to 43.6%) given the upcoming EUV revenue recognition. Overall, our changes (see details below) have an average negative impact of 3% on our EPS estimates for FY16/17/18e.
- With a lack of visibility due to EUV revenue recognition, risks on DUV tools demand during H2, risks regarding LT demand and the timing EUV insertion points, we keep our Sell rating.**

	1 M	3 M	6 M	31/12/15
Absolute perf.	-2.7%	9.6%	9.0%	2.6%
Semiconductors	-2.6%	6.2%	1.0%	-5.0%
DJ Stoxx 600	2.6%	8.8%	-3.3%	-4.1%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	6,287	6,487	7,415	8,742
% change		3.2%	14.3%	17.9%
EBITDA	1,864	1,774	2,337	3,031
EBIT	1,565	1,469	2,017	2,666
% change		-6.1%	37.3%	32.2%
Net income	1,387	1,266	1,758	2,353
% change		-8.7%	38.8%	33.8%

	2015	2016e	2017e	2018e
Operating margin	24.9	22.7	27.2	30.5
Net margin	22.1	19.5	23.7	26.9
ROE	16.5	15.5	20.0	23.8
ROCE	22.9	19.1	26.4	25.9
Gearing	-27.2	-17.5	-23.6	-7.4

(EUR)	2015	2016e	2017e	2018e
EPS	3.21	3.02	4.26	5.82
% change	-	-6.0%	41.2%	36.6%
P/E	26.4x	28.1x	19.9x	14.6x
FCF yield (%)	4.0%	1.8%	5.0%	NM
Dividends (EUR)	0.70	1.05	1.21	1.39
Div yield (%)	0.8%	1.2%	1.4%	1.6%
EV/Sales	5.5x	5.4x	4.7x	4.1x
EV/EBITDA	18.5x	19.9x	14.8x	11.9x
EV/EBIT	22.0x	24.0x	17.2x	13.5x



- Based on our estimates, ASML's shares trade at a 2016e P/E ratio of 25.6x and a 2016e PEG ratio of 1.2x.

NEXT CATALYSTS

- 20th July 2016: FQ2-16 results.

Detailed P&L

[EURm]	1Q16	2Q16e	3Q16e	4Q16e	FY16e	FY17e	FY18e
Total Group	1333	1734	1652	1767	6487	7415	8742
<i>Q/Q growth</i>	-7.0%	30.1%	-4.8%	7.0%	3.2%	14.3%	17.9%
<i>Y/Y growth</i>	-19.2%	4.9%	6.6%	23.2%	3.2%	14.3%	17.9%
Cost of goods sold	-765	-1003	-912	-979	-3658	-4004	-4616
Gross margin	42.6%	42.2%	44.8%	44.6%	43.6%	46.0%	47.2%
R&D	-275	-271	-271	-269	-1087	-1097	-1162
SG&A	-89	-90	-89	-89	-357	-371	-376
Other operating income	23	23	20	18	84	74	79
Adj. EBIT	228	393	400	448	1469	2017	2666
<i>adj. operating margin</i>	17.1%	22.7%	24.2%	25.4%	22.7%	27.2%	30.5%
Net financial result	-4	-3	-3	-7	-17	-19	-23
Income tax	-26	-51	-52	-57	-186	-240	-291
<i>tax rate</i>	-11.8%	-13.0%	-13.0%	-13.0%	-12.8%	-12.0%	-11.0%
Adj. Net income	198	339	345	384	1266	1758	2353
Diluted adjusted EPS	0.46	0.80	0.82	0.92	3.02	4.26	5.82

Source: Bryan Garnier & Co. ests.

P&L changes highlights

[EURm]	Old			New			Old vs. New
	2016e	2017e	2018e	2016e	2017e	2018e	avg. Δ%
Net revenue	6485	7419	8742	6487	7415	8742	0%
<i>% change</i>	3.1%	14.4%	17.8%	3.2%	14.3%	17.9%	
Adj. EBIT	1615	2025	2666	1469	2017	2666	-3%
<i>Adj. operating margin</i>	24.9%	27.3%	30.5%	22.7%	27.2%	30.5%	
Adj. EPS	3.3	4.3	5.8	3.0	4.3	5.8	-3%

Source: Bryan Garnier & Co. ests.

[Click here to download](#)



Analyst :
Dorian Terral
33(0) 1.56.68.75.92
dterral@bryangarnier.com

Sector Team :
Richard-Maxime Beaudoux
Thomas Coudry
Gregory Ramirez

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 57.6%

NEUTRAL ratings 33.8%

SELL ratings 8.6%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			Geneva
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..